Zoetis Inc. (ZTS) Stock Score, Valuation & Financial Research
Zoetis Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 57/100.
Quick answer for ZTS
Zoetis Inc. currently has a Wall Street Score of 57/100. The stored market price is $73.41. Its financial score is 29/100. Its valuation score is 92/100. These figures are a research snapshot, not a buy or sell recommendation.
What Zoetis Inc. does
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and se
ZTS financial snapshot
- Wall Street Score:
- 57/100
- Current price:
- $73.41
- Market capitalization:
- $30.78B
- Revenue:
- $9.51B
- Net income:
- $2.64B
- Free cash flow:
- $2.28B
- Cash:
- $1.94B
- Total debt:
- $9.24B
- EPS:
- 6.03
- P/E ratio:
- 12.2x
- Financial score:
- 29/100
- Valuation score:
- 92/100
- Revenue score:
- 27/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $2.28B, showing positive cash generation.
- The balance sheet shows $1.94B of cash versus $9.24B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 92/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 29/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ZTS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.